Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
mi
from
Elkhorn, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
mi
from
Elkhorn, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Oncology Alliance, SC - Milwaukee - East
mi
from
Glendale, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Oncology Alliance, SC - Milwaukee - East
mi
from
Glendale, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Dean Medical Center - Madison
mi
from
Madison, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Dean Medical Center - Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Saint Joseph's Hospital
mi
from
Marshfield, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Saint Joseph's Hospital
mi
from
Marshfield, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Aurora Sinai Medical Center
mi
from
Milwaukee, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Aurora Sinai Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Medical Consultants, Limited
mi
from
Milwaukee, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Medical Consultants, Limited
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Tom Baker Cancer Centre - Calgary
mi
from
Calgary,
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Tom Baker Cancer Centre - Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates
Status: Enrolling
Updated:  10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates
Status: Enrolling
Updated: 10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Elizabeth Registry for Low Grade Ovarian Cancer
The Elizabeth Registry for Low Grade Ovarian Cancer
Status: Enrolling
Updated:  10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Elizabeth Registry for Low Grade Ovarian Cancer
The Elizabeth Registry for Low Grade Ovarian Cancer
Status: Enrolling
Updated: 10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator
Status: Enrolling
Updated:  10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator
Status: Enrolling
Updated: 10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
Status: Enrolling
Updated:  10/5/2015
Beth Israel Medical Center - Philipps Ambulatory Care Center
mi
from
New York, NY
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
Status: Enrolling
Updated: 10/5/2015
Beth Israel Medical Center - Philipps Ambulatory Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Georgetown University Medical Center
mi
from
Washington,
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Indiana University Department of Urology
mi
from
Indianapolis, IN
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Indiana University Department of Urology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Hematology Oncology Consultants
mi
from
Greenbelt, MD
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Hematology Oncology Consultants
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Myron I Murdock MD LLC
mi
from
Greenbelt, MD
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Myron I Murdock MD LLC
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
NYU Cancer Institute
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Mount Sinai School of Medicine Department of Urology
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Mount Sinai School of Medicine Department of Urology
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Columbia University Medical Center
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
GU Oncology Research Program
mi
from
Durham, NC
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
GU Oncology Research Program
mi
from
Durham, NC
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Urology of Virginia/ Sentara
mi
from
Norfolk, VA
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Urology of Virginia/ Sentara
mi
from
Norfolk, VA
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Virginia Mason Medical Center Urology and Renal Transplantation
mi
from
Seattle, WA
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Virginia Mason Medical Center Urology and Renal Transplantation
mi
from
Seattle, WA
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Aurora Advanced Healthcare, Inc.
mi
from
Wauwatosa, WI
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Aurora Advanced Healthcare, Inc.
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Medical Center- La Jolla
mi
from
La Jolla, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Medical Center- La Jolla
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
UCSD Medical Center - Hillcrest
mi
from
San Diego, CA
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
UCSD Medical Center - Hillcrest
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
mi
from
Washington,
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
mi
from
Washington,
Click here to add this to my saved trials
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated:  10/6/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Status: Enrolling
Updated: 10/6/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Click here to add this to my saved trials